Suspended

A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Back Acne

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

MOE Antimicrobial Plasma Treatment System

Device
Who is being recruted

Sebaceous Gland Diseases+2

+ Skin Diseases

+ Skin and Connective Tissue Diseases

From 18 to 40 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: August 2012
See protocol details

Summary

Principal SponsorMoe Medical Devices
Last updated: September 14, 2017
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2012

Actual date on which the first participant was enrolled.

The purpose of this study is to evaluate the safety of treating human skin with atmospheric plasma and get an initial evaluation of the efficacy of this treatment for acne.

Principal SponsorMoe Medical Devices
Last updated: September 14, 2017
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

8 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 40 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Sebaceous Gland DiseasesSkin DiseasesSkin and Connective Tissue DiseasesAcneiform EruptionsAcne Vulgaris

Criteria

Inclusion Criteria: Males and non-pregnant, non-nursing females age 18-40 years old. Presence of clinically-evident back acne. Minimum of 20 non-inflammatory lesions (open and closed comedones) Minimum of 30 total lesions (sum of inflammatory and non-inflammatory) Subject must have measurable sebum production. Subjects must be in generally good health. Must be able and willing to comply with the requirements of the protocol. Exclusion Criteria: Any nodulo-cystic lesions at Baseline Pregnancy or breast feeding Use of acne devices or systemic therapy with antibiotics within four months prior to start and throughout the duration of the study Intake of any oral retinoids within four months prior to study start and throughout the duration of the study Topical use of topical retinoids within two weeks prior to study start and throughout the duration of the study Topical use of antibiotics, steroids and/or other non-retinoid topical acne products within two weeks prior to study start and throughout the duration of the study Use of an experimental drug or device within 30 days prior to study start; Intake of hormonal therapy within 3 months prior to study start Use of topical products on the back containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids. Concomitant use of mega-doses of certain vitamins, such as vitamin D (>2000IU QD) vitamin B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital. Procedures on the skin of the back such as chemical or laser peel, microdermabrasion, photodynamic therapy) within the past 2 weeks or during the study. History or evidence of other skin conditions or diseases that may require concurrent therapy or may interfere with the evaluation of the study medication Any significant medical conditions that could confound the interpretation of the study results. History of/or current skin cancer cancer Use of tanning booths, sun lamps within the past 2 weeks or during the study Any metallic implants or prostheses in the vicinity of the treatment site (such as shoulders, back, spine, pacemakers, etc.). Any known photosensitivity disorders felt by the investigators to preclude safe inclusion in the study. History of significant post-inflammatory hyperpigmentation at the sites of acne lesions. History of or is currently immunocompromised.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Plasma applied to back for up to 20 minutes, twice/week for 4 weeks

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Clinical Unit for Research Trials and Outcomes in Skin (CURTIS)

Boston, United StatesOpen Clinical Unit for Research Trials and Outcomes in Skin (CURTIS) in Google Maps
SuspendedOne Study Center